Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 324 | Poster Presentation | BDB001, a Toll-Like Receptor 7 and 8 (TLR7/8) Agonist, can be safely administered intravenously and shows clinical responses in advanced solid tumors. | Manish Patel, MD; Drew Rasco, MD; Melissa L. Johnson, MD; Anthony W. Tolcher, MD; Lixin Li, PhD; Adam Zong, PhD; Alexander Chung, PhD; Robert H. Andtbacka, MD, CM; | In-Progress Clinical Trials | COVID and Immunotherapy; Adoptive immunotherapy; Clinical study; Clinical trial; Cytokine; Dendritic cell; Monocyte/Macrophage; Solid tumors; TLR |
| 325 | Poster Presentation | Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells | Gerard J. Criner, MD; Mehrdad Mobasher, MD, MPH; Craig M. Hill, PhD; Shenshen Hu, PhD; Suresh Mahabhashyam, MD, MPH; Joshua Brody, MD; Thomas U. Marron, MD, PhD; Stephen Willingham, PhD; Richard A. Miller, MD; | In-Progress Clinical Trials | COVID and Immunotherapy; Antibody; B cell; Clinical study; Clinical trial; Immune adjuvant; Vaccine |
| 326 | Poster Presentation | SARS-CoV-2 specific T-cells in TIL from patients with epithelial cancer | Pedro Noronha; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Eric D. Sousa; Jéssica O. Kamiki; Patrícia A. António; Carolina Condenço; Inês Silva; Andreia Maia, PhD student; Mireia Castillo-Martin; António Beltran; Carlos Carvalho, MD; Joana R. Lerias, PhD; Alimuddin Zumla; Markus J. Maeurer, MD, PhD, FRCP(London); | In-Progress Clinical Trials | COVID and Immunotherapy; Clinical study; Tumor infiltrating lymphocytes (TILs) |
| 327 | Poster Presentation | Study of anti-PD-1 antibody multimodal combination as first-line treatment on time window of advanced solid tumor | Jian Shi, MD; Baoen Shan; Junyan Wang; Jiayin Liu; Rongfeng Liu; Yujie Shan; | In-Progress Clinical Trials | COVID and Immunotherapy; Angiogenesis; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical trial; Gene expression; Immune toxicity; Solid tumors; Targeted therapy |
| 440 | Poster Presentation | Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer | Guo Gui Sun; Jing Hao Jia; Peng Gao; Xue Min Yao; Ming Da Chen; Wei Nan Yao; Lu Sun; Wei Wang; | Combination Immunotherapies | COVID and Immunotherapy; Checkpoint blockade; Chemotherapy; Clinical study; Immune monitoring; Immune suppression; Solid tumors; T cell; Tumor evasion; Tumor microenvironment |
| 475 | Oral Presentation | Incidental finding of colorectal cancer in a COVID-19 patient, followed by deep profiling of SARS-CoV-2-associated immune landscape and tumour microenvironment | Chun Chau Lawrence Cheung, BA, MMedSc; Chun Chau Lawrence Cheung, BA, MMedSc; Xinru Lim; Denise Goh, BBiomedSc (Hons); Tracy Zhijun Tien; Jeffrey Chun Tatt Lim; Thuan Tong Tan; Shirin Kalimuddin; Jia Lin Ng; Jenny Guek-Hong Low; Joe P. Yeong, MD, PhD; Kiat Hon T. Lim; | COVID and Immunotherapy | COVID and Immunotherapy; Biomarkers; Chemokine; Cytokine; Immune contexture; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 476 | Poster Presentation | AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19 | Tingting Zhong, MS; Zhaoliang Huang, BSc; Xinghua Pang, BSc; na chen, MD; Konyew Kwek, PhD; Chris Wynne, MB, ChB; Adam Konpa, MS; Xiaoping Jin, PhD; Yu Xia, PhD; Maxwell Zhongmin Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Antibody; B cell |
| 477 | Poster Presentation | Deep Learning to Drive COVID-19 Rapid Drug Repurposing | Sarah Kolitz, PhD; Jason Kim, PhD; Jenny Zhang, PhD; Yoonjeong Cha, PhD; Sailaja Battula, PhD; Rebecca Kusko, PhD; Rajaraman Krishnan, PhD; Benjamin J. Zeskind, PhD, MBA; Howard L. Kaufman, MD; | COVID and Immunotherapy | COVID and Immunotherapy; Bioinformatics; Systems biology |
| 478 | Poster Presentation | Translation of a therapeutic neoantigen vaccine workflow to SARS-CoV-2 vaccine development | Christof C. Smith, PhD; Christof C. Smith, PhD; Sarah Entwistle; Caryn Willis; Steven P. Vensko; Wolfgang Beck, AB; Jason Garness; Maria J. Sambade; Eric Routh; Kelly Olsen; Brandon Carpenter; Kaylee Gentry; Maria Fadri; Misha Fini; Amber Washington; Julia Kodysh, MSc; Timothy O'Donnell; Carsten Haber; Kirsten Heiss; Volker Stadler; Erik Garrison; Oliver C. Grant; Robert J. Woods; Mark Heise; Benjamin G. Vincent, MD; Alexander Rubinsteyn, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Antibody; B cell; Neoantigens; T cell; Vaccine |
| 479 | Poster Presentation | A lymph-node targeted amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2 | Martin Steinbuck, PhD; Peter C. DeMuth, PhD; Lochana Seenappa, MS; Christopher M. Haqq, MD, PhD; Aniela Jakubowski; Lisa K. McNeil, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Immune adjuvant; T cell; Vaccine |
| 480 | Oral Presentation | Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12 | Shawn M. Jensen, PhD; Christopher G. Twitty, PhD; Christopher C. Paustian, PhD; Madelein Laws; Glenna McDonnell, MS; Keith Wegmann; Tarsem L. Moudgil, MS; Michael E. Afentoulis, MSc; Mia Han; Kellie Malloy Foerter; David A. Canton, PhD; Jack Y. Lee; Bianca A. Nguyen; John Rodriguez; Kim Jaffe, PhD; Brian D. Piening, PhD; Carlo B. Bifulco, MD; Daniel J. O'Connor; Walter J. Urba, MD, PhD; Rom S. Leidner, MD; Traci L. Hilton, PhD; Hong-Ming Hu, PhD; Bernard A. Fox, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Antibody; B cell; Cytokine; Immune adjuvant; Immune monitoring; T cell; Vaccine |
| 481 | Poster Presentation | Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors | Kevin Tyan, BA; Ai-Tram N. Bui, BA; Anita Giobbie-Hurder, MS; Isaac A. Klein, MD, PhD; Michael P. Manos, BA; Leyre Zubiri, MD, PhD; Kerry L. Reynolds, MD; Shilpa Grover, MD, MPH; Gerald L. Weinhouse, MD; Patrick A. Ott, MD, PhD; Nicole R. LeBoeuf, MD, MPH; Osama E. Rahma, MD; | COVID and Immunotherapy | COVID and Immunotherapy; Checkpoint blockade; Immune toxicity |
| 482 | Poster Presentation | COVID-19 in patients with lung cancer receiving immunotherapy. A report from an spanish academic center. | David Viñal; Laura Gutierrez; Julia Villamayor; Oliver Higuera; Dario Sanchez Cabrero; Javier De Castro; | COVID and Immunotherapy | COVID and Immunotherapy; Clinical study; Solid tumors |
| 483 | Poster Presentation | Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis | Olivier OD. Demaria, PhD; Julien Carvelli, MD; Nassima Chouaki Benmansour, MD; Joanna Fares, PhD; Luciana Batista, PhD; Marie-Laure Thibult, PhD; Ariane Morel, PhD; Sabrina Carpentier, PhD; Romain Remark, PhD; Agnes Represa; Frederic Vely, PhD; Mikael Ebbo, MD; Nicolas Schleinitz, MD; Robert Zerbib, MSc; Yannis Morel, PhD; Eric Vivier, PhD; Olivier OD. Demaria, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Antibody; Biomarkers; Cytokine; Inflammation; MDSC; Monocyte/Macrophage; Myeloid cells |
| 567 | Poster Presentation | MDK1319/MDK-701: A potent fully efficacious peptidyl agonist of IL-7Rαγc, designed with no reference to cytokine or receptor structure and unrelated to IL-7, fused to an Fc-domain for PK enhancement | William J. Dower, PhD; Alice V. Bakker, BA; Steven E. Cwirla; Prarthana Joshi, ME; Praechompoo Pongtornpipat, MS; Blake M. Williams, MS; Sandra M. Wang, BSc; Michael C. Needels, PhD; Ronald W. Barrett, PhD; | Immune-stimulants and immune modulators | COVID and Immunotherapy; CAR T cells; Cytokine; Immune adjuvant; T cell; T cell lineages; Vaccine |
| 825 | Oral Presentation | Deep immune profiling of SARS-CoV-2 associated immune microenvironment in cancer tissues from recovered COVID-19 patients | Denise Goh, BBiomedSc (Hons); Chun Chau Lawrence Cheung, BA, MMedSc; Xinru Lim; Tracy Zhijun Tien; Jeffrey Chun Tatt Lim; Sanjna Nilesh Nerurkar; Loong Shihleone; Peng Chung Cheow; Chung Yip Chan; Ye Xin Koh; Thuan Tong Tan; Shirin Kalimuddin; Wai Meng David Tai; Jia Lin Ng; Jenny Guek-Hong Low; Joe Poh Sheng Yeong; Tony Kiat Hon Lim; | COVID and Immunotherapy | COVID and Immunotherapy; Biomarkers; Chemokine; Cytokine; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 826 | Poster Presentation | Risk of COVID-19 infection among patients receiving immune checkpoint inhibitor therapy: A tertiary care hospital system collaboration with the Massachusetts Department of Health | William Murphy, AB; Vartan Pahalyants, BA; Nicholas Theodosakis, MD; Leyre Zubiri, MD, PhD; Monina Klevens, DDS; Evelyn Lilly, MD; Kerry L. Reynolds, MD; Yevgeniy R. Semenov, MD, MA; | COVID and Immunotherapy | COVID and Immunotherapy; Epidemiology |
